Nanosizing: a formulation approach for poorly-water-soluble compounds.

Poorly-water-soluble compounds are difficult to develop as drug products using conventional formulation techniques and are frequently abandoned early in discovery. The use of media milling technology to formulate poorly-water-soluble drugs as nanocrystalline particles offers the opportunity to address many of the deficiencies associated with this class of molecules. NanoCrystal Technology is an attrition process wherein large micron size drug crystals are media milled in a water-based stabilizer solution. The process generates physically stable dispersions consisting of nanometer-sized drug crystals. Nanocrystalline particles are a suitable delivery system for all commonly used routes of administration, i.e. oral, injectable (IV, SC, and IM) and topical applications. In addition, aqueous dispersions of nanoparticles can be post-processed into tablets, capsules, fast-melts and lyophilized for sterile product applications. The technology has been successfully incorporated into all phases of the drug development cycle from identification of new chemical entities to refurbishing marketed products for improving their performance and value.

[1]  J. Kreuter,et al.  Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants , 1990 .

[2]  Joseph P. Remington,et al.  Remington's pharmaceutical sciences , 2016 .

[3]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[4]  G. W. Pace,et al.  Novel injectable formulations of insoluble drugs , 1999 .

[5]  S. Venkatesh,et al.  Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.

[6]  Lisbeth Illum,et al.  Long circulating microparticulate drug carriers , 1995 .

[7]  Jean W. Tom,et al.  Particle formation with supercritical fluids—a review , 1991 .

[8]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[9]  Papisov,et al.  Theoretical considerations of RES-avoiding liposomes: Molecular mechanics and chemistry of liposome interactions. , 1998, Advanced drug delivery reviews.

[10]  C. Lipinski Poor aqueous solubility-an industry wide problem in drug discovery , 2002 .

[11]  Lisbeth Illum,et al.  Modification of the Copolymers Poloxamer 407 and Poloxamine 908 can Affect the Physical and Biological Properties of Surface Modified Nanospheres , 1998, Pharmaceutical Research.

[12]  M. Lawrence,et al.  Microemulsion-based media as novel drug delivery systems , 2000 .

[13]  Hiroshi Maeda,et al.  Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues , 1998, Japanese journal of cancer research : Gann.

[14]  H. Bosch,et al.  Sterile Filtration of NanoCrystal™ Drug Formulations , 1997 .

[15]  T. Allen,et al.  Liposomes , 2012, Drugs.

[16]  R. W. Wood,et al.  Nebulization of NanoCrystals™: Production of a Respirable Solid-in-Liquid-in-Air Colloidal Dispersion , 2004, Pharmaceutical Research.

[17]  J Dressman,et al.  Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[18]  G. Liversidge,et al.  Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .

[19]  Clive G. Wilson,et al.  Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape , 1982 .

[20]  G Gregoriadis,et al.  Engineering liposomes for drug delivery: progress and problems. , 1995, Trends in biotechnology.

[21]  Stephen Byrn,et al.  Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations , 1995, Pharmaceutical Research.

[22]  B. Aungst,et al.  Intestinal permeation enhancers. , 2000, Journal of pharmaceutical sciences.

[23]  Y Zhang,et al.  Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[24]  G. Na,et al.  Physical Stability of Ethyl Diatrizoate Nanocrystalline Suspension in Steam Sterilization , 1999, Pharmaceutical Research.

[25]  R. Juliano Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions , 1988 .

[26]  J. Dressman,et al.  Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. , 1997, Advanced drug delivery reviews.

[27]  P Couvreur,et al.  Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[28]  H. Kusuhara,et al.  The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. , 1998, Journal of pharmaceutical sciences.

[29]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[30]  Roger A. Rajewski,et al.  Cyclodextrins: Their Future in Drug Formulation and Delivery , 1997, Pharmaceutical Research.

[31]  J. Breitenbach Melt extrusion: from process to drug delivery technology. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[32]  G. Liversidge,et al.  Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats , 1995 .

[33]  S. Davis,et al.  Nanoparticles in drug delivery. , 1987, Critical reviews in therapeutic drug carrier systems.

[34]  A. Kibbe Handbook of Pharmaceutical Excipients , 2009 .

[35]  M. Nakano Places of emulsions in drug delivery. , 2000, Advanced drug delivery reviews.

[36]  J. Robinson,et al.  Bioadhesive-based dosage forms: the next generation. , 2000, Journal of pharmaceutical sciences.

[37]  M. Brewster,et al.  Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. , 1996, Journal of pharmaceutical sciences.

[38]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[39]  Michael J Akers,et al.  Excipient-drug interactions in parenteral formulations. , 2002, Journal of pharmaceutical sciences.

[40]  F. Martin,et al.  Tumoricidal effect of macrophages exposed to adriamycin in vivo or in vitro. , 1982, Cancer research.

[41]  Beate Bittner,et al.  Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. , 2002, Current opinion in drug discovery & development.

[42]  M. Woodle,et al.  Controlling liposome blood clearance by surface-grafted polymers. , 1998, Advanced drug delivery reviews.

[43]  Floyd Top ten considerations in the development of parenteral emulsions. , 1999, Pharmaceutical science & technology today.

[44]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Serajuddin,et al.  Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. , 1999, Journal of pharmaceutical sciences.

[46]  P. Couvreur,et al.  Nanoparticles as microcarriers for anticancer drugs , 1990 .

[47]  S. Arii,et al.  Tumoricidal activity of Kupffer cells augmented by anticancer drugs. , 1992, Life sciences.

[48]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[49]  J. M. Shaw,et al.  Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs , 1996, Pharmaceutical Research.

[50]  K. Johnston,et al.  Solution-Based Particle Formation of Pharmaceutical Powders by Supercritical or Compressed Fluid Co2 and Cryogenic Spray-Freezing Technologies , 2001, Drug development and industrial pharmacy.

[51]  Christos Reppas,et al.  Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.

[52]  M. Dewhirst,et al.  Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. , 2000, Cancer research.

[53]  E. Bacon,et al.  Pharmacokinetics and hepatic disposition of bis[1-(ethoxycarbonyl)propyl]5-acetylamino-2,4,6-triiodoisophthalate in rats and isolated perfused rat livers. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[54]  R K Jain,et al.  Delivery of Molecular Medicine to Solid Tumors , 1996, Science.